Journal Article
. 2007 Jun; 10(3):171-7.
doi: 10.1007/s11938-007-0010-6.

Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis

Brian W Behm 1 Stephen J Bickston  
Affiliations
  • PMID: 17547855
  •     6 References
  •     5 citations

Abstract

Infliximab is arguably the first major advance in therapy for inflammatory bowel disease in more than a quarter of a century. Although it is important to distinguish efficacy from effectiveness, the data from clinical practice mirror those from randomized controlled trials. Infliximab has proven efficacious for luminal manifestations of Crohn's disease (CD) regardless of location. It also has proven efficacy in the subset of penetrating disease to the skin and perianal area, and it increases rates of steroid-free remission. These benefits are reflected in improved quality of life, with limited data showing that infliximab can decrease rates of hospitalization and CD-related surgery. Infliximab also has proven to be efficacious in patients with ulcerative colitis (UC) and has increased rates of steroid-free remission. Whether infliximab will have an impact on the risk of colorectal cancer in UC and Crohn's colitis has yet to be determined. The combination of strong evidence from large randomized controlled trials with substantial examination of use in the practice setting has moved biologic therapy with infliximab from novel to mainstream. In this review, the data for the efficacy of infliximab in controlled trials will be discussed in the context of real world effectiveness.

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
T Ljung, P Karlén, +5 authors, R Löfberg.
Gut, 2004 May 13; 53(6). PMID: 15138212    Free PMC article.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
S R Targan, S B Hanauer, +6 authors, P J Rutgeerts.
N Engl J Med, 1997 Oct 09; 337(15). PMID: 9321530
Highly Cited.
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
A K Akobeng, M Zachos.
Cochrane Database Syst Rev, 2004 Feb 20; (1). PMID: 14974022
Systematic Review.
New concepts in the pathophysiology of inflammatory bowel disease.
Giorgos Bamias, Mark R Nyce, +3 authors, American Physiological Society.
Ann Intern Med, 2005 Dec 21; 143(12). PMID: 16365470
Review.
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
Gary R Lichtenstein, Songkai Yan, Mohan Bala, Stephen Hanauer.
Am J Gastroenterol, 2003 Dec 23; 99(1). PMID: 14687148
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Gary R Lichtenstein, Maria T Abreu, +2 authors, American Gastroenterological Association.
Gastroenterology, 2006 Mar 15; 130(3). PMID: 16530532
Review.
Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging.
Long Sun, Hua Wu, Yong-Song Guan.
World J Gastroenterol, 2008 Feb 02; 14(6). PMID: 18240342    Free PMC article.
Review.
Infliximab for the treatment of plaque psoriasis.
Jennifer S Gall, Robert E Kalb.
Biologics, 2008 Mar 01; 2(1). PMID: 19707434    Free PMC article.
Cost effectiveness of treatments for inflammatory bowel disease.
Keith Bodger.
Pharmacoeconomics, 2011 Jan 29; 29(5). PMID: 21271748
Review.
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.
Matti Waterman, Wei Xu, +6 authors, Mark S Silverberg.
Inflamm Bowel Dis, 2011 Aug 11; 17(9). PMID: 21830272    Free PMC article.
Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
John McConnell, Simona Parvulescu-Codrea, +7 authors, Beth Woodward.
World J Gastrointest Pharmacol Ther, 2013 Mar 22; 3(5). PMID: 23515325    Free PMC article.